Posts by Dominic Warrino, Ph.D.

Dominic's role is to serve as scientific and technical advisor for both clients and internal teams for development, validation, and application of bioanalytical, immunogenicity, and biomarker methods for large molecule therapeutics. He has 20 years of experience developing and validating immunological assays for biotechnology and pharmaceutical companies.

KCAS-blog-thumb_2022_LBA-and-LCMSMS Blogs
Read article Combining the Benefits of LBA and LC-MS/MS for Pharmacodynamics at KCAS

Pharmacodynamics (PD) is defined as the study of the biochemical and physiological effects of drugs and the mechanisms of their actions. Where pharmacokinetics looks at how the organism processes the drug, pharmacodynamics studies how…

KCAS-blog-thumb_biomarker-questions Blogs
Read article Questions to Consider About Your Biomarker Project

I have been studying Biological Markers (biomarkers) for over 25 years, but last 5 years they have exploded and become a key bioanalytical component to a drug’s success. Biomarkers are used to support drug…

KCAS-blog-thumb_YouCanStillDoItHere-1 Blogs
Read article Trouble with your lab shutting down? You can still do it here.

The long-term economic consequences of the COVID-19 virus are yet to be determined. However, short term it is having major impact on research & drug development so companies are adapting in order to survive.

PATTERN_ORANGE_1320x780_2 Blogs
Read article Putting the Luminex to Work: Which of KCAS’ newest biomarkers is right for you?

Biomarker is a broad term and can mean so many different things depending upon the scientific discipline. For Bioanalytical biomarker analysis – and specifically for CROs equipped with 9 different platforms to measure biomarkers and a cell culture suite with up to 19 color flow cytometry all under one roof…

Thumb_July_Pharma_Changes-Biopharma Blogs
Read article Changes in LBA Biopharma at KCAS

The bioanalytical landscape for support of biopharmaceuticals (biologics or large molecules) and biomarker testing is an ever changing map. The industry is currently focused on low level sensitivity, data integrity, and compliance with the…

PATTERN_AMBER_1320x780_3 Blogs
Read article Protein Characterization at KCAS

Protein characterization is a broad term describing the profile or fingerprint of a large molecule’s (or biologic’s) physical, chemical, and biological properties. Characterization of the protein will test the purity, activity, and the quantity…

PATTERN_AMBER_1320x780 Blogs
Read article Old vs. New Technologies at KCAS

Adoption of technology has a life cycle that typically follows a bell-shaped curve. There are early adopters, early majority, late majority, and laggards. Adopting technology early comes with a risk, as not all technologies are widely adopted and many are very short lived. Adopting late also comes with a risk,…

PATTERN_BLUE_1320x780_3 Blogs
Read article Cell-Based Biomarker & PD Support at KCAS

As the Bioanalytical support for drug development continues to grow, more and more scientists are requiring more complex assays. Two examples are cell based assays and what we refer to as live cell assays.

KCAS-Blog_Thumbnail-Banner_Cancer-Vaccines-1 Blogs
Read article Emerging Immuno-oncology Therapies

Immuno-oncology is a growing field. The goal is to augment the patient’s immune system to attack the cancer cells. The current lines of treatment for cancer are radiation, chemotherapy, and surgical resection. If these treatments do not work, physicians can seek alternative treatments, such as immune-oncology therapeutics. Two emerging immune-oncology…

PATTERN_BLUE_1320x780 Blogs
Read article MSD 54-plex: Ready When You Are

KCAS is the first GLP laboratory to qualify all 54 biomarkers offered as a V-Plex (Validated Plex) by MSD. The a la carte style allows for customization of panels that will fit the exact…

PATTERN_BLUE_1320x780 Blogs
Read article Evaluating New Modalities

Measuring new biotherapeutic modalities such as cellular therapies are not well defined in the regulatory landscape. Currently no white papers or guidelines are available to help navigate the murky waters of quantifying new modalities, which is why the AAPS PK focus group has set a course toward providing the field…

PATTERN_ORANGE_1320x780_3 Blogs
Read article Optimizing ELISA Kits for Biomarkers at KCAS

What you don’t know about how an off-the-shelf Biomarker kit is evaluated and qualified can significantly compromise your biomarker data. Running the kit using the manufacturer’s instructions without systematically testing the accuracy/precision (A/P), range of quantification (ROQ), dilutional linearity (DL), stability, and selectivity can jeopardized the interpretation of the results.